Literature DB >> 25446781

Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population.

J Jiang1, X Zhang2, R Huo1, X Li1, Y Yang3, Z Gai4, M Xu1, L Shen1, L Cai1, C Wan1, B Li1, L He5, S Qin1.   

Abstract

Drug-induced liver injury (DILI) is caused by unpredictable adverse drug reaction due mainly to the accumulation of hepatotoxic compounds in the liver resulting in significant damage. Drug-metabolizing enzymes have been prime targets for molecular studies relevant to DILI. The gene UGT1A9 mainly expresses in the liver and has an important role in drug metabolism. The Han Chinese has a very long and complex demographic history, and the population stratification arising from the interplay of different geographic areas may influence the polymorphism pattern. We selected 260 healthy subjects in three different geographic areas (including Xian, Shanghai and Liuzhou) for systemic screening and analysis of single-nucleotide polymorphisms (SNPs) in the promoter region of UGT1A9. Eight SNPs were identified and no regional disparity exists among the three populations. Based on these results, 213 DILI patients from all over the Chinese mainland were further recruited to investigate possible association between UGT1A9 and DILI. We observed statistically significant associations between SNP rs2741045 and DILI at both allele and genotype levels (allele: P=0.032; genotype: P=0.029; after Bonferroni correction). Also, multivariate interaction analysis discovered the interaction between rs2741045 and age associated with DILI significantly. This is the first such screening study to investigate the association between UGT1A9 promoter polymorphisms and DILI in the Chinese population and it could provide the basis for further study of DILI mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25446781     DOI: 10.1038/tpj.2014.75

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  35 in total

1.  Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China.

Authors:  Shengying Qin; Lu Shen; Aiping Zhang; Jing Xie; Wen Shen; Lingling Chen; Jimin Tang; Yuyu Xiong; Lun Yang; Yongyong Shi; Guoyin Feng; Lin He; Qinghe Xing
Journal:  Genomics       Date:  2008-07-15       Impact factor: 5.736

2.  Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Authors:  E Martignoni; M Cosentino; M Ferrari; G Porta; E Mattarucchi; F Marino; S Lecchini; G Nappi
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

Review 3.  Pharmacogenomics in drug induced liver injury.

Authors:  Raúl J Andrade; José A G Agúndez; M Isabel Lucena; Carmen Martínez; Raquel Cueto; Elena García-Martín
Journal:  Curr Drug Metab       Date:  2009-11       Impact factor: 3.731

4.  Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

Authors:  Ann K Daly; Guruprasad P Aithal; Julian B S Leathart; Richard A Swainsbury; Tarana Singh Dang; Christopher P Day
Journal:  Gastroenterology       Date:  2006-11-17       Impact factor: 22.682

Review 5.  The role of metabolic activation in drug-induced hepatotoxicity.

Authors:  B Kevin Park; Neil R Kitteringham; James L Maggs; Munir Pirmohamed; Dominic P Williams
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  Association of CYP2C9*2 with bosentan-induced liver injury.

Authors:  S M Markova; T De Marco; N Bendjilali; E A Kobashigawa; J Mefford; J Sodhi; H Le; C Zhang; J Halladay; A E Rettie; C Khojasteh; D McGlothlin; A H B Wu; W-C Hsueh; J S Witte; J B Schwartz; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

7.  Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptide antibodies.

Authors:  S Ikushiro; Y Emi; T Iyanagi
Journal:  Arch Biochem Biophys       Date:  1995-12-20       Impact factor: 4.013

8.  Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.

Authors:  Sony Tuteja; Nikolaos T Pyrsopoulos; William R Wolowich; Kamran Khanmoradi; David M Levi; Gennaro Selvaggi; Geoffrey Weisbaum; Andreas G Tzakis; Eugene R Schiff
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

9.  Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.

Authors:  Oliwia Zakerska; Marzena Skrzypczak-Zielinska; Adam Mikstacki; Barbara Tamowicz; Bianka Malengowska; Marlena Szalata; Ryszard Slomski
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-25       Impact factor: 2.441

10.  Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population.

Authors:  Jing Yang; Lei Cai; Haiyan Huang; Bingya Liu; Qiang Wu
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

View more
  3 in total

Review 1.  Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity.

Authors:  Jawad Ahmad; Joseph A Odin
Journal:  Clin Liver Dis       Date:  2016-10-14       Impact factor: 6.126

2.  Proteome and transcriptome analysis revealed florfenicol via affected drug metabolism and lipid metabolism induce liver injury of broilers.

Authors:  Chao Han; Yuqing Cui; Yiwei Guo; Di Zhang; Xiao Wang; Yumeng Geng; Wanyu Shi; Yongzhan Bao
Journal:  Poult Sci       Date:  2021-05-04       Impact factor: 3.352

Review 3.  Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.

Authors:  Philip Sarges; Joshua M Steinberg; James H Lewis
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.